V W Tsai1, H P Zhang1, R Manandhar1, K K M Lee-Ng1, H Lebhar2, C P Marquis2, Y Husaini1, A Sainsbury3, D A Brown1, S N Breit1. 1. St Vincent's Centre for Applied Medical Research, St Vincent's Hospital and University of New South Wales, Sydney, New South Wales, Australia. 2. School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, New South Wales, Australia. 3. The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: To test the potential efficacy of recombinant macrophage inhibitory cytokine-1 (MIC-1/GDF15) as an obesity therapeutic. METHODS: Male C57BL/6 J mice, either fed on normal chow or high-fat diet for 16 weeks to induce diet-induced obesity, were infused with either recombinant MIC-1/GDF15 or vehicle for 34 days by osmotic minipump. During the experimental period metabolic parameters were measured. Blood and tissue were collected for analysis of inflammatory markers. RESULTS: MIC-1/GDF15 decreased food intake and body weight of high-fat-fed and chow-fed mice compared with their vehicle-treated control mice. MIC-1/GDF15 reduced body weight, accompanied by greater reduction in fat mass in high-fat-fed mice compared to its effect on chow-fed mice. Further, whilst MIC-1/GDF15-treated chow-fed mice lost lean as well as fat mass, MIC-1/GDF15-treated high-fat-fed mice lost fat mass alone. This reduction in body weight and adiposity was due largely to reduced food intake, but MIC-1/GDF15-treated high-fat-fed mice also displayed increased energy expenditure that may be due to increased thermogenesis. MIC-1/GDF15-treated high-fat-fed mice also had higher circulating level of adiponectin and lower tissue expression, and circulating levels of leptin and inflammatory mediators associated with insulin resistance. Peripheral insulin and glucose intolerance were improved in both MIC-1/GDF15-treated high-fat-fed and chow-fed mice compared to that of their vehicle-treated control mice. CONCLUSIONS: MIC-1/GDF15 is highly effective in reducing adiposity and correcting the metabolic dysfunction of mice with high-fat fed. These studies suggest that MIC-1/GDF15 may be a candidate anti-obesity therapeutic.
OBJECTIVES: To test the potential efficacy of recombinant macrophage inhibitory cytokine-1 (MIC-1/GDF15) as an obesity therapeutic. METHODS: Male C57BL/6 J mice, either fed on normal chow or high-fat diet for 16 weeks to induce diet-induced obesity, were infused with either recombinant MIC-1/GDF15 or vehicle for 34 days by osmotic minipump. During the experimental period metabolic parameters were measured. Blood and tissue were collected for analysis of inflammatory markers. RESULTS:MIC-1/GDF15 decreased food intake and body weight of high-fat-fed and chow-fed mice compared with their vehicle-treated control mice. MIC-1/GDF15 reduced body weight, accompanied by greater reduction in fat mass in high-fat-fed mice compared to its effect on chow-fed mice. Further, whilst MIC-1/GDF15-treated chow-fed mice lost lean as well as fat mass, MIC-1/GDF15-treated high-fat-fed mice lost fat mass alone. This reduction in body weight and adiposity was due largely to reduced food intake, but MIC-1/GDF15-treated high-fat-fed mice also displayed increased energy expenditure that may be due to increased thermogenesis. MIC-1/GDF15-treated high-fat-fed mice also had higher circulating level of adiponectin and lower tissue expression, and circulating levels of leptin and inflammatory mediators associated with insulin resistance. Peripheral insulin and glucose intolerance were improved in both MIC-1/GDF15-treated high-fat-fed and chow-fed mice compared to that of their vehicle-treated control mice. CONCLUSIONS:MIC-1/GDF15 is highly effective in reducing adiposity and correcting the metabolic dysfunction of mice with high-fat fed. These studies suggest that MIC-1/GDF15 may be a candidate anti-obesity therapeutic.
Authors: Heiko Johnen; Tamara Kuffner; David A Brown; Ben J Wu; Roland Stocker; Samuel N Breit Journal: Cardiovasc Pathol Date: 2012-03-02 Impact factor: 2.185
Authors: Asne R Bauskin; David A Brown; Simon Junankar; Krishan K Rasiah; Sarah Eggleton; Mark Hunter; Tao Liu; Dave Smith; Tamara Kuffner; Greg J Pankhurst; Heiko Johnen; Pamela J Russell; Wade Barret; Phillip D Stricker; John J Grygiel; James G Kench; Susan M Henshall; Robert L Sutherland; Samuel N Breit Journal: Cancer Res Date: 2005-03-15 Impact factor: 12.701
Authors: David A Brown; Robyn L Ward; Philip Buckhaults; Tao Liu; Katharine E Romans; Nicholas J Hawkins; Asne R Bauskin; Kenneth W Kinzler; Bert Vogelstein; Samuel N Breit Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: David A Brown; Samuel N Breit; Julie Buring; W Douglas Fairlie; Asne R Bauskin; Tao Liu; Paul M Ridker Journal: Lancet Date: 2002-06-22 Impact factor: 79.321
Authors: Laurence Macia; Vicky Wang-Wei Tsai; Amy D Nguyen; Heiko Johnen; Tamara Kuffner; Yan-Chuan Shi; Shu Lin; Herbert Herzog; David A Brown; Samuel N Breit; Amanda Sainsbury Journal: PLoS One Date: 2012-04-13 Impact factor: 3.240
Authors: Tito Borner; Hallie S Wald; Misgana Y Ghidewon; Bei Zhang; Zhidan Wu; Bart C De Jonghe; Danna Breen; Harvey J Grill Journal: Cell Rep Date: 2020-04-21 Impact factor: 9.423
Authors: Philipp Glosse; Abul Fajol; Frank Hirche; Martina Feger; Jakob Voelkl; Florian Lang; Gabriele I Stangl; Michael Föller Journal: Nutr Diabetes Date: 2018-05-29 Impact factor: 5.097
Authors: Timon E Adolph; Felix Grabherr; Lisa Mayr; Christoph Grander; Barbara Enrich; Alexander R Moschen; Herbert Tilg Journal: J Obes Date: 2018-11-08